Non-nucleoside inhibitors include UZH1a [114] (a high-nanomolar inhibitor of METTL3 with selectivity and cell permeability), SAM adenosine part pocket filled with UZH1a, UZH2 [115] (an optimized UZH1a analogue) with significantly improved solubility and metabolic stability and selective inhibition of METTL16 and METTL1 compared to UZH1a, and STM2457 [116] (a highly efficient and selective METTL3 catalytic inhibitor) that binds to SAM binding sites and exerts its anti-AML effect without markedly affecting normal hematopoiesis. This evidence concerns the gene METTL3 and acute myeloid leukemia.